Zydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.
In line with this, the group now has 203 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.371.5 as compared to the previous close of Rs. 382.1. The total number of shares traded during the day was 156050 in over 2205 trades.
The stock hit an intraday high of Rs. 383.55 and intraday low of 369. The net turnover during the day was Rs. 58566796.